Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reaffirmed by stock analysts at Cann in a research note issued on Monday. They currently have a $17.50 price objective on the stock. Cann’s price target would suggest a potential upside of 29.63% from the company’s previous close.

The analysts wrote, “Kura Oncology had three positive presentations for its lead compound, Tipifarnib, at the 2017 American Society of Hematology meeting, from December 9-11. These included preliminary phase II analysis in CMML and PTCL, and a biomarker study. We found these studies very encouraging for Tipifarnib’s use in hematologic cancers. Our outlook for 2020-22 remains basically unchanged, and we estimate that Tipifarnib could result in sales as early as 2019. We currently estimate Tipifarnib could result in 2022 product sales of $1.1 billion. The data presented at 2017 ASH are very supportive of our outlook.””

Several other equities research analysts have also commented on the stock. Cowen started coverage on shares of Kura Oncology in a report on Thursday, September 7th. They issued an “outperform” rating on the stock. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Saturday, September 9th. ValuEngine raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Citigroup increased their target price on shares of Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Finally, Oppenheimer set a $18.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $17.90.

Shares of Kura Oncology (NASDAQ:KURA) opened at $13.50 on Monday. Kura Oncology has a 1-year low of $5.50 and a 1-year high of $17.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). equities research analysts forecast that Kura Oncology will post -1.45 EPS for the current year.

Several hedge funds have recently bought and sold shares of KURA. Candriam Luxembourg S.C.A. purchased a new stake in shares of Kura Oncology during the 3rd quarter worth about $8,073,000. Morgan Stanley boosted its stake in shares of Kura Oncology by 175.5% during the 1st quarter. Morgan Stanley now owns 430,428 shares of the company’s stock worth $3,788,000 after acquiring an additional 274,166 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of Kura Oncology during the 3rd quarter worth about $2,884,000. State Street Corp purchased a new stake in shares of Kura Oncology during the 2nd quarter worth about $1,394,000. Finally, Northern Trust Corp raised its position in shares of Kura Oncology by 939.3% during the 2nd quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after purchasing an additional 133,293 shares during the last quarter. 64.26% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/cann-reiterates-buy-rating-for-kura-oncology-kura/1760641.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.